Skip to main content
. 2022 Jun;11(6):1027–1037. doi: 10.21037/tlcr-22-376

Figure 2.

Figure 2

Kaplan-Meier curves of PFS (A) and OS (B) of patients with advanced NSCLC who received ICI-based treatment beyond progression with prior immunotherapy. mPFS, median progression-free survival; mOS, median overall survival; NSCLC, non-small cell lung cancer; ICI, immune checkpoint inhibitor.